Brief: PolyPid Announces Completion Of Enrollment In Phase 3 Shield I Trial Of D-Plex₁₀₀
31/05/2022 12:51
May 31 (Reuters) - PolyPid Ltd PYPD.O :
* POLYPID ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 3
SHIELD I
TRIAL OF D-PLEX₁₀₀ FOR PREVENTION OF SURGICAL SITE INFECTIONS IN
ABDOMINAL SURGERY
* POLYPID LTD- POTENTIAL NDA AND MAA SUBMISSIONS PLANNED FOR
FIRST
HALF OF 2023
* POLYPID LTD- LOOK FORWARD TO AVAILABILITY OF TOP-LINE
RESULTS
FROM SHIELD I BY END OF Q3 OF 2022
Source text for Eikon: ID:nGNX6s7DB8
Further company coverage: PYPD.O
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA